

Supplementary Information

Accelerated resolution of inflammation underlies sex differences in inflammatory responses in humans

Krishnaraj S. Rathod, Vikas Kapil, Shanti Velmurugan, Rayomand S. Khambata, Umme Siddique, Saima Khan, Sven Van Eijl,, Jascharanpreet Bansal, Kavi Pitrola, Christopher Shaw, Romain A. Collas, Federica Marelli-Berg, Jesmond Dalli, Amrita Ahluwalia *

*** Corresponding author:**

**Professor Amrita Ahluwalia
Prof of Vascular Pharmacology
Barts & The London Medical School
Queen Mary University of London
Charterhouse Square,
London, EC1M 6BQ
Email: a.ahluwalia@qmul.ac.uk
Tel: +44 207 882 8377
Fax: +44 207 882 5619**

Supplementary Tables

Table S1

The effect of typhoid on the expression of platelet activation markers and platelet activity in healthy volunteers. Data are shown for % P-selectin expression in males and females following PBS treatment and in response to ADP (3 and 10 µM) or collagen (3 and 10 µg/ml) at baseline, 8 hours and 32 hours post vaccine. For % platelet monocyte aggregates levels were measured at baseline, 8 hours and 32 hours post-vaccine. Data are shown as mean ± s.e.mean and statistical analysis conducted using two-way ANOVA to determine the influence of sex for n=10 male and n=12 female volunteers (2 samples lost due to technical difficulties). Statistical significance was tested using two-way ANOVA with Sidak's post-hoc analysis.

| | Males | | | Females | | | Sex comparison P Value |
|----------------------------------|------------|------------|------------|------------|------------|------------|---------------------------|
| | Baseline | 8 hours | 32 hours | Baseline | 8 hours | 32 hours | |
| % P-Selectin expression | | | | | | | |
| PBS | 2.3 ± 1.4 | 0.7 ± 0.2 | 2.2 ± 1.2 | 1.0 ± 0.2 | 0.5 ± 0.1 | 0.8 ± 0.3 | 0.517 |
| Collagen 1 µg/ml | 2.2 ± 0.7 | 1.3 ± 0.3 | 2.6 ± 1.1 | 2.3 ± 0.7 | 1.1 ± 0.2 | 1.2 ± 0.2 | 0.567 |
| Collagen 3 µg/ml | 3.7 ± 0.9 | 3.2 ± 0.8 | 4.2 ± 1.6 | 3.8 ± 1.3 | 2.7 ± 0.6 | 2.2 ± 0.4 | 0.448 |
| ADP 3 µM | 9.1 ± 2.6 | 6.8 ± 1.3 | 4.2 ± 1.6 | 8.9 ± 2.1 | 12.3 ± 3.7 | 10.8 ± 3.3 | 0.723 |
| ADP 10 µM | 10.9 ± 3.3 | 7.1 ± 1.8 | 12.5 ± 3.3 | 12.0 ± 2.5 | 12.9 ± 3.0 | 13.8 ± 3.6 | 0.587 |
| % PMA expression | 31.5 ± 4.2 | 34.2 ± 6.4 | 26.8 ± 4.3 | 27.8 ± 5.4 | 34.4 ± 6.0 | 33.1 ± 4.7 | 0.611 |
| Platelet Aggregation (AU) | | | | | | | |
| PBS | 7.2 ± 2.1 | 8.8 ± 3.0 | 8.2 ± 2.3 | 9.2 ± 2.0 | 13.5 ± 2.5 | 8.1 ± 2.3 | 0.268 |
| Collagen 1 µg/ml | 59.5 ± 3.4 | 61.6 ± 5.2 | 54.8 ± 4.0 | 60.2 ± 5.3 | 74.6 ± 5.1 | 61.3 ± 5.2 | 0.086 |
| Collagen 3 µg/ml | 78.9 ± 3.7 | 91.5 ± 4.9 | 75.1 ± 3.9 | 83.8 ± 5.9 | 99.6 ± 5.9 | 76.8 ± 6.5 | 0.245 |
| ADP 3 µM | 35.1 ± 4.1 | 37.8 ± 4.1 | 37.7 ± 5.4 | 46.3 ± 5.8 | 54.4 ± 5.1 | 43.2 ± 5.5 | 0.008 |
| ADP 10 µM | 47.8 ± 4.1 | 49.9 ± 4.3 | 43.9 ± 3.7 | 57.0 ± 4.4 | 68.6 ± 3.5 | 56.9 ± 4.8 | 0.0002 |

Table S2

Vascular measures at baseline and at 8 and 32 hours following typhoid vaccination Data are shown as mean ± SD with statistical significance determined using two-way ANOVA with post-hoc Sidak's tests shown as * for P<0.05, **P <0.01, ***P <0.001, ****P <0.0001 for comparison of time-points between the sexes and no significant differences for within group comparisons to baseline.

| | Males (n=12) | | | Females (n=12) | | | Sex comparison |
|---------------------------------------|--------------|---------------|-------------|----------------|------------|------------|----------------|
| | Baseline | 8 hours | 32 hours | Baseline | 8 hours | 32 hours | |
| Ultrasound | | | | | | | |
| Baseline brachial artery diameter, mm | 3.8 ± 0.5*** | 3.8 ± 0.5**** | 3.8 ± 0.4** | 3.1 ± 0.3 | 3.1 ± 0.4 | 3.2 ± 0.4 | <0.0001 |
| Time to peak diameter, min | 6.7 ± 0.5 | 6.7 ± 0.7 | 6.7 ± 0.8 | 6.7 ± 0.2 | 6.8 ± 0.2 | 6.8 ± 0.2 | 0.492 |
| PWA | | | | | | | |
| Augmentation index, % | 13.3 ± 1.9 | 13.8 ± 1.2 | 13.5 ± 1.7* | 12.1 ± 1.4 | 11.6 ± 2.2 | 11.9 ± 1.9 | 0.24 |
| PWV, m/s | 6.7 ± 0.1 | 6.7 ± 0.1 | 6.7 ± 0.2* | 6.3 ± 0.1 | 6.2 ± 0.2 | 6.2 ± 0.1 | <0.0001 |

Table S3

Blood differentials and CRP levels in male and female healthy volunteers at baseline and post cantharidin-induced blister harvest. Data are shown as mean \pm SD with statistical significance determined using two-way ANOVA with post-hoc Sidak's tests (note there were no significant differences between the sexes or on the effects of cantharidin on circulating markers or within sex).

| | | Hb (g/dL) | Platelet count ($\times 10^9/L$) | WBC ($\times 10^{11}/L$) | Neutrophils ($\times 10^9/L$) | Lymphocytes ($\times 10^9/L$) | Monocytes ($\times 10^9/L$) | CRP (mg/L) |
|----------------|--------------|----------------|------------------------------------|----------------------------|---------------------------------|---------------------------------|-------------------------------|------------|
| Male | Baseline | 15.0 \pm 0.3 | 234.7 \pm 15.2 | 5.4 \pm 0.3 | 3.0 \pm 0.3 | 1.8 \pm 0.1 | 0.4 \pm 0.04 | <5 |
| | Post-blister | 15.0 \pm 0.3 | 242.2 \pm 12.9 | 5.6 \pm 0.4 | 3.2 \pm 0.3 | 1.8 \pm 0.1 | 0.4 \pm 0.04 | <5 |
| Female | Baseline | 13.1 \pm 0.3 | 258.0 \pm 12.0 | 6.3 \pm 0.5 | 3.8 \pm 0.4 | 1.9 \pm 0.1 | 0.4 \pm 0.02 | <5 |
| | Post-blister | 12.7 \pm 0.2 | 259.9 \pm 12.2 | 6.0 \pm 0.3 | 3.3 \pm 0.2 | 2.0 \pm 0.1 | 0.4 \pm 0.02 | <5 |
| Sex Comparison | | <0.0001 | 0.123 | 0.109 | 0.133 | 0.133 | 0.859 | 0 |

Table S4 Cytokine/chemokine array of 24 hour cantharidin-induced blister supernatants in male and female healthy volunteers. Data are shown as mean \pm SD with statistical significance determined using two-way ANOVA with post-hoc Sidak's tests shown as ** for P <0.01 for comparison of time-points between the sexes and no significant differences for within group comparisons to baseline.

| | | IL-6 (pg/ml) | IL-10 (pg/ml) | CCL-5 (pg/ml) | CXCL-1 (pg/ml) | IL-8 (pg/ml) | MCP-1 (pg/ml) |
|----------------|------|-----------------|-----------------|-----------------|-------------------|--------------------|-------------------|
| Male | 24 h | 4361 \pm 1182 | 6.6 \pm 2.3 | 11.5 \pm 1.8 | 1046 \pm 606.6 | 5716 \pm 1453 | 6139 \pm 2141 |
| | 72 h | 3250 \pm 1178 | 48.1 \pm 26.7 | 38.5 \pm 26.0 | 224.5 \pm 36.0 | 3675 \pm 563.8 | 224.4 \pm 26.86 |
| Female | 24 h | 5087 \pm 1697 | 18.0 \pm 7.3 | 15.5 \pm 2.7 | 4224 \pm 1809 | 13383 \pm 2771** | 9658 \pm 3113 |
| | 72 h | 5240 \pm 3007 | 30.6 \pm 0.0 | 10.7 \pm 0 | 380.4 \pm 124.3 | 5511 \pm 9376 | 302.6 \pm 93.2 |
| Sex comparison | | 0.452 | 0.653 | 0.375 | 0.221 | 0.0484 | 0.527 |

Table S5 Blister exudate LM-SPM profiles. Exudates were collected from male (n=13) and female volunteers (n=11) 24h after cantharidin application and supernatants were profiling using LC-MS/MS based profiling. Results are mean \pm s.e.m. with statistical significance determined using Student's 2-tailed unpaired t-test. - = below limit, limit \approx 0.1 pg

| DHA bioactive metabolome | Q1 | Q3 | Lipid mediators levels (pg/50μL) | | | <i>p</i> value |
|--------------------------|-----|-----|----------------------------------|-------|-------------|----------------|
| | | | Female | | Male | |
| RvD1 | 375 | 215 | 1.6 | \pm | 1.1 | 0.317 |
| RvD2 | 375 | 215 | 0.4 | \pm | 0.7 | 0.120 |
| RvD3 | 375 | 147 | 0.0 | \pm | 0.1 | 0.143 |
| RvD4 | 375 | 101 | - | | - | |
| RvD5 | 359 | 199 | 0.3 | \pm | 0.3 | 0.176 |
| RvD6 | 359 | 159 | - | | - | |
| 17R-RvD1 | 375 | 215 | 1.8 | \pm | 1.7 | 0.051 |
| 17R-RvD3 | 375 | 147 | 0.0 | \pm | 0.1 | 0.246 |
| PD1 | 359 | 153 | 0.3 | \pm | 0.6 | 0.046 |
| 10S,17S-diHDHA (PDX) | 359 | 153 | 0.7 | \pm | 0.6 | 0.463 |
| MaR1 | 359 | 250 | 2.5 | \pm | 6.4 | 0.195 |
| 7S,14S-diHDHA | 359 | 221 | 0.1 | \pm | 0.3 | 0.201 |
| 17-HDHA | 343 | 245 | 22.7 | \pm | 17.5 | 0.115 |
| 14-HDHA | 343 | 205 | 194.2 | \pm | 108.2 | 0.263 |
| 7-HDHA | 343 | 141 | 2.7 | \pm | 1.6 | 0.282 |
| 4-HDHA | 343 | 101 | 3.6 | \pm | 1.7 | 0.264 |
| DHA | 327 | 283 | 3031.3 | \pm | 1309.2 | 0.33 |
| EPA bioactive metabolome | | | | | | |
| RvE1 | 349 | 161 | 0.4 | \pm | 1.0 | 0.403 |
| RvE2 | 333 | 199 | 1.0 | \pm | 1.1 | 0.344 |
| RvE3 | 333 | 245 | 4.0 | \pm | 6.6 | 0.125 |
| 18-HEPE | 317 | 259 | 2.1 | \pm | 4.8 | 0.288 |
| 15-HEPE | 317 | 219 | 7.9 | \pm | 11.3 | 0.094 |
| 12-HEPE | 317 | 179 | 20.1 | \pm | 52.2 | 0.390 |
| 5-HEPE | 317 | 115 | 0.4 | \pm | 1.2 | 0.23.2 |
| EPA | 301 | 257 | 975.5 | \pm | 622.1 | 0.210 |
| AA bioactive metabolome | | | | | | |
| LXA ₄ | 351 | 115 | - | | - | |
| LXB ₄ | 351 | 221 | 5.4 | \pm | 3.6 | 0.062 |
| 5S,15S-diHETE | 335 | 115 | 15.0 | \pm | 19.6 | 0.193 |
| AT-LXA ₄ | 351 | 115 | 0.2 | \pm | 0.3 | 0.493 |
| AT-LXB ₄ | 351 | 221 | 0.6 | \pm | 1.2 | 0.198 |
| LTB ₄ | 335 | 195 | 0.6 | \pm | 0.3 | 0.037 |
| PGD ₂ | 351 | 189 | 16.2 | \pm | 12.9 | 0.032 |
| PGE ₂ | 351 | 189 | 228.1 | \pm | 205.6 | 0.070 |
| PGF _{2α} | 353 | 193 | 1116.6 | \pm | 550.0 | 0.076 |
| TxB ₂ | 369 | 169 | 805.2 | \pm | 796.4 | 0.093 |
| 20-HETE | 319 | 301 | 15.5 | \pm | 11.9 | 0.246 |
| 15-HETE | 319 | 219 | 144.8 | \pm | 211.0 | 0.082 |
| 12-HETE | 319 | 179 | 551.2 | \pm | 223.4 | 0.374 |
| 5-HETE | 319 | 115 | 9.3 | \pm | 5.3 | 0.098 |
| AA | 303 | 259 | 4320.9 | \pm | 1980.6 | 0.319 |

Table S6 Lipid mediator profiles in plasma from male or female volunteers following typhoid vaccination Plasma was collected and LM levels were assessed using LM-profiling. Results are expressed as pg/mL; mean \pm s.e.m. ; n = 4 volunteers per group. - = below limit, limit \approx 0.1 pg

| DHA bioactive metabolome | Q1 | Q3 | Lipid mediators levels (pg/mL) | | <i>p</i> value |
|-------------------------------------|-----|-----|---------------------------------|---------------------------------|----------------|
| | | | Male | Female | |
| RvD1 | 375 | 233 | 0.1 \pm 0.0 | 0.1 \pm 0.0 | 0.280 |
| RvD2 | 375 | 141 | 0.3 \pm 0.1 | 0.4 \pm 0.2 | 0.312 |
| RvD3 | 375 | 147 | 0.2 \pm 0.1 | 0.1 \pm 0.0 | 0.187 |
| RvD4 | 375 | 101 | 0.5 \pm 0.5 | 0.1 \pm 0.1 | 0.230 |
| RvD5 | 359 | 199 | 1.2 \pm 0.2 | 2.0 \pm 0.7 | 0.152 |
| RvD6 | 359 | 101 | 0.3 \pm 0.1 | 0.2 \pm 0.1 | 0.340 |
| 17R-RvD1 | 375 | 141 | 0.1 \pm 0.0 | 0.1 \pm 0.1 | 0.312 |
| 17R-RvD3 | 375 | 147 | 0.2 \pm 0.1 | 0.1 \pm 0.0 | 0.187 |
| PD1 | 359 | 153 | 0.2 \pm 0.0 | 0.2 \pm 0.1 | 0.296 |
| 17R-PD1 | 359 | 153 | 0.2 \pm 0.1 | 0.1 \pm 0.1 | 0.329 |
| 22-OH-PD1 | 375 | 153 | 0.4 \pm 0.4 | 0.7 \pm 0.7 | 0.343 |
| 10S,17S-diHDHA (PDX) | 359 | 153 | 0.6 \pm 0.0 | 0.9 \pm 0.3 | 0.098 |
| MaR1 | 359 | 221 | - | - | |
| MaR2 | 359 | 191 | 2.9 \pm 1.3 | 2.5 \pm 1.0 | 0.395 |
| 22-OH-MaR1 | 375 | 221 | 0.4 \pm 0.4 | 0.1 \pm 0.2 | 0.247 |
| 7S,14S-diHDHA | 359 | 221 | - | - | 0.232 |
| 4S,14S-diHDHA | 359 | 101 | 0.3 \pm 0.3 | 0.1 \pm 0.1 | 0.178 |
| EPA bioactive metabolome | | | | | |
| RvE1 | 349 | 161 | 0.2 \pm 0.1 | 0.4 \pm 0.1 | 0.118 |
| RvE2 | 333 | 159 | 0.1 \pm 0.1 | - | 0.369 |
| RvE3 | 333 | 201 | 0.4 \pm 0.2 | 0.9 \pm 0.4 | 0.094 |
| AA bioactive metabolome | | | | | |
| LXA ₄ | 351 | 217 | 0.1 \pm 0.0 | 0.1 \pm 0.0 | 0.298 |
| LXB ₄ | 351 | 221 | 5.2 \pm 2.6 | - | 0.028 |
| 5S,15S-diHETE | 335 | 235 | 4.9 \pm 2.6 | 1.1 \pm 0.8 | 0.082 |
| AT-LXA ₄ | 351 | 217 | 0.2 \pm 0.2 | 0.1 \pm 0.1 | 0.317 |
| AT-LXB ₄ | 351 | 221 | 1.1 \pm 0.6 | 1.2 \pm 0.8 | 0.440 |
| LTB ₄ | 335 | 195 | 0.6 \pm 0.0 | 0.5 \pm 0.0 | 0.006 |
| 6-trans- LTB ₄ | 335 | 195 | 0.1 \pm 0.0 | - | 0.168 |
| 12-epi-6-trans- LTB ₄ | 335 | 195 | 0.2 \pm 0.1 | - | 0.099 |
| 5S,12S-diHETE | 335 | 195 | 0.1 \pm 0.0 | 0.1 \pm 0.0 | 0.414 |
| 20-OH-LTB ₄ | 351 | 195 | 0.1 \pm 0.0 | - | 0.085 |
| PGD ₂ | 351 | 189 | 3.5 \pm 1.8 | 4.4 \pm 2.6 | 0.382 |
| PGE ₂ | 351 | 189 | 5.7 \pm 2.4 | 6.9 \pm 3.7 | 0.379 |
| PGF _{2α} | 353 | 193 | 3.8 \pm 1.0 | 6.0 \pm 3.0 | 0.220 |
| TxB ₂ | 369 | 169 | 97.8 \pm 36.3 | 108.7 \pm 52.7 | 0.426 |

Supplementary Figures




Figure S1 – Changes in expression of CD11b, CD62L and CD162 on monocytes, CD4+ and CD8+ lymphocytes in male and female healthy volunteers measured at baseline, 8 hours and 32 hours following typhoid vaccine. Data expressed as mean \pm s.e.mean for n=12 for each sex for all the panels. Statistical significance determined using two-way ANOVA with Sidak's post-hoc analysis for all the panels. MFI = Median fluorescence intensity.




Figure S2 Correlations between FMD responses in healthy volunteers and levels of plasma NO metabolites NO_2^- , NO_3^- and NO_x in females (A-C) and males (D-F). Data from pre-vaccine baseline and 8 and 32 hours post-vaccine are collated. All graphs show Pearson linear regression, and statistical significance of r-value for all the panels.




Figure S3 – Representative dot plots to identify leucocyte sub-populations collected in cantharidin induced blister fluid in healthy volunteers: **A-B)** Characteristic FSC/SSC dot plot from a 24hrs and 72hrs blister fluid respectively; **C)** Density dot plot of neutrophils (yellow-gated cells) confirmed by anti-CD16b+ binding; **D)** Density dot plot of monocytes showing presence of CD14+/CD16- classical inflammatory (IM) monocytes (green-gated), CD14+/CD16+ intermediate monocytes (blue-gated) and a fraction of CD14lo/CD16++ resident (RM) monocytes confirmed by appropriate binding patterns with anti-CD14 and/or anti-CD16; **E)** Density dot plot of lymphocytes (red-gated cells) confirmed by anti-CD3 binding and **F)** Density dot plot showing T-cell sub-types with anti-CD4+ (orange-gated cells) and anti-CD8+ (blue-gated cells) binding.




Figure S4 – Intermediate Monocyte count in cantharidin-induced blister fluid at 24 hours and 72 hours post application in healthy volunteers (male n=13-15, female n=14-16). Data shown as mean \pm s.e.mean with statistical significance determined using two-way ANOVA to compare between sexes on each day; not significant.




Figure S5 – Resident Monocyte in cantharidin-induced blister fluid at 24 hours and 72 hours post application in healthy volunteers (male n=13-15, female n=14-16). Data shown as mean ± s.e.mean with statistical significance determined using two-way ANOVA to compare between sexes on each day; not significant.

Figure S6. Distinct plasma LM-SPM profiles in males and females following typhoid vaccination. Plasma was collected for healthy volunteers following typhoid vaccine administration and LM levels were assessed using LM-profiling (see methods for details). (A) MS-MS fragmentation and diagnostic ions employed for LXB₄ and RvE1 identification. m/z, mass-to-charge ratio; M-H, molecular ion. (B) *top panel* 2-dimentional score plot of human plasma LM-SPM profiles. *Bottom panel* 2-dimentional loading plot. Grey ellipse in the score plot denotes 95% confidence regions. Results are representative n=4 male and n=4 female healthy volunteers. (C-D) Cumulative levels for each of the bioactive LM families identified. Results are means±s.e.m n=4 volunteers per group. * p<0.05 vs Male volunteer plasma values.

